Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development, manufacture, and distribution of therapies for the treatment of central and peripheral nervous system in Italy and internationally. The company offers Xadago (safinamide) for the treatment of Parkinson's disease. Its pipeline of products include Sarizotan for patients with Rett syndrome; Evenamide, a first add-on therapy for the treatment of patients with positive symptoms of schizophrenia; and Ralfinamide for patients with specific rare pain indications. Newron Pharmaceuticals S.p.A. has a collaboration agreement with Meiji Seika Pharma Co., Ltd. for the development and commercialization of safinamide in Japan and Asian territories. The company was founded in 1998 and is headquartered in Bresso, Italy.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
WebN/A
PhoneN/A
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.17 million
Profitability
Miscellaneous
Employees24
Next Earnings DateN/A
OptionableNot Optionable
Newron Pharmaceuticals (OTCMKTS:NWPHF) Frequently Asked Questions
What is Newron Pharmaceuticals' stock symbol?
Newron Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NWPHF."
Has Newron Pharmaceuticals been receiving favorable news coverage?
News articles about NWPHF stock have been trending negative on Sunday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Newron Pharmaceuticals earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 8.0 out of 10, meaning that recent press coverage is very likely to have an impact on the stock's share price in the immediate future.
Who are some of Newron Pharmaceuticals' key competitors?
Some companies that are related to Newron Pharmaceuticals include Kura Oncology (KURA), Stemline Therapeutics (STML), Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Organogenesis (ORGO), Lexicon Pharmaceuticals (LXRX), Crinetics Pharmaceuticals (CRNX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA), Viking Therapeutics (VKTX), CannTrust (CTST), Odonate Therapeutics (ODT), Puma Biotechnology (PBYI), OvaScience (OVAS) and Obseva (OBSV).
What other stocks do shareholders of Newron Pharmaceuticals own?
Who are Newron Pharmaceuticals' key executives?
Newron Pharmaceuticals' management team includes the folowing people:
- Mr. Stefan Weber, CEO & Exec. Director (Age 54)
- Mr. Roberto Galli, VP of Fin.
- Mr. Marco Caremi, Exec. VP of Bus. Devel. (Age 62)
- Dr. Ravi Anand, Chief Medical Officer (Age 62)
- Mr. Dennis Dionne, VP of Commercial Affairs (Age 69)
How do I buy shares of Newron Pharmaceuticals?
Shares of NWPHF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Newron Pharmaceuticals' stock price today?
One share of NWPHF stock can currently be purchased for approximately $9.25.
How big of a company is Newron Pharmaceuticals?
Newron Pharmaceuticals has a market capitalization of $165.02 million and generates $15.17 million in revenue each year. Newron Pharmaceuticals employs 24 workers across the globe.
MarketBeat Community Rating for Newron Pharmaceuticals (OTCMKTS NWPHF)
MarketBeat's community ratings are surveys of what our community members think about Newron Pharmaceuticals and other stocks. Vote "Outperform" if you believe NWPHF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NWPHF will underperform the S&P 500 over the long term. You may vote once every thirty days.
